2025 Q4 -tulosraportti
27 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Irtoamispäivä 27.3.
4,91%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 056 | - | - | ||
| 455 | - | - | ||
| 155 | - | - | ||
| 1 055 | - | - | ||
| 45 | - | - |
Ylin
240,3VWAP
Alin
230,85VaihtoMäärä
3 037,4 13 000 452
VWAP
Ylin
240,3Alin
230,85VaihtoMäärä
3 037,4 13 000 452
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| ABG Sundal Collier ASA | 153 | 153 | 0 | 153 |
| Anonyymi | 13 000 299 | 13 000 299 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| ABG Sundal Collier ASA | 153 | 153 | 0 | 153 |
| Anonyymi | 13 000 299 | 13 000 299 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 min sittenIsn't it a bit wild that nicorette is allowed to cost so much? I don't understand why they are allowed to sell so expensively and us naive Novo supporters are punished with the regulation whip by the dominatrix.
·2 min sittenMedical researchers have discovered that semaglutide can reverse the debilitating tissue damage caused by osteoarthritis, the world's most common form of arthritis. The drug behind Ozempic and Wegovy is best known for treating type 2 diabetes and helping people lose weight. But the new study showed that semaglutide appears to protect joints in mice through a mechanism that is not about relieving pressure through weight loss. Instead, the drug reprograms the metabolism of cells that synthesize and maintain healthy cartilage, allowing them to generate more energy. "This work not only highlights the potential off-target effect of semaglutide as an effective drug for treating metabolic osteoarthritis," the team from China and the USA writes in their published paper, "but also reveals a weight-loss-independent repair mechanism." In addition to mouse experiments, the researchers also conducted a randomized human trial to assess the effects of semaglutide on pain, mobility, and tissue degradation in individuals with osteoarthritis and obesity. Link is found on pro investér Where the full link can be read
·35 min sittenTo all the pessimists!!! USA is recovering and Novo at 237 😂 Sleep well 💤2 min sitten2 min sittenDamn it, I hope it can wait a bit until I get my deposit back so that I can lose that money too
·1 t sittenJust bring on the deals that can signal an aggressive approach. One could suitably start by entering the fray regarding Nanexa… what negotiations are ongoing is impossible to figure out, but it's embarrassing that 2025 ended as it did. It was always a company that NN should have fully taken over.
38 min sitten · Muokattu38 min sitten · MuokattuIt's a falling knife. Hands off. Falling since 2024.·35 min sittenCouldn't agree more. They haven't been skilled and aggressive enough - and still aren't. It's long since Crunch Time and from now until summer they really need to shift into a completely different gear if they are to break out of this deadlock they've gotten into. I don't think this tactic of playing on being a "solid" company that earns "good money" is a discourse that will do anything but harm. The market has understood that they still have a solid business running. But the market has also long since smelled that it's a business that almost lacks both 4th and 5th gear in the gearbox. One must at least hope that Mike "I've never missed a budget" D has done exactly what it takes to keep it going: they've aimed so low now that they can't avoid missing (and maybe they've set it up so they can upgrade later in the year, who knows). But I just think it would be a very good time to step on the gas in some way. It fundamentally surprises me that they aren't trying to find a way to direct focus elsewhere through some aggressive acquisitions. It just seems so incredibly one-sided by now, all this NN vs LLY talk. There's a lot of talk about which of them wins the obesity race - but in the long run, it's also about who manages to do something other than put everything into chasing obesity market shares and the market's favor based on who just has a couple of percent better this than the others... It's become too crazy, you know..
·1 t sittenThe whales have now recovered after the rocket-fireworks and are ready to inject money into Novo again. BIG money. I.e. whale money. We can therefore expect the price to rise to 240 tomorrow, then a bit more subdued up towards 280 by the end of the month. Then FOMO will arise. The scaredy-cats will join the train again, and then, well, the rest is history
·10 min sittenIt continues to trickle towards 220 tomorrow.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
27 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Irtoamispäivä 27.3.
4,91%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 min sittenIsn't it a bit wild that nicorette is allowed to cost so much? I don't understand why they are allowed to sell so expensively and us naive Novo supporters are punished with the regulation whip by the dominatrix.
- ·2 min sittenMedical researchers have discovered that semaglutide can reverse the debilitating tissue damage caused by osteoarthritis, the world's most common form of arthritis. The drug behind Ozempic and Wegovy is best known for treating type 2 diabetes and helping people lose weight. But the new study showed that semaglutide appears to protect joints in mice through a mechanism that is not about relieving pressure through weight loss. Instead, the drug reprograms the metabolism of cells that synthesize and maintain healthy cartilage, allowing them to generate more energy. "This work not only highlights the potential off-target effect of semaglutide as an effective drug for treating metabolic osteoarthritis," the team from China and the USA writes in their published paper, "but also reveals a weight-loss-independent repair mechanism." In addition to mouse experiments, the researchers also conducted a randomized human trial to assess the effects of semaglutide on pain, mobility, and tissue degradation in individuals with osteoarthritis and obesity. Link is found on pro investér Where the full link can be read
- ·35 min sittenTo all the pessimists!!! USA is recovering and Novo at 237 😂 Sleep well 💤2 min sitten2 min sittenDamn it, I hope it can wait a bit until I get my deposit back so that I can lose that money too
- ·1 t sittenJust bring on the deals that can signal an aggressive approach. One could suitably start by entering the fray regarding Nanexa… what negotiations are ongoing is impossible to figure out, but it's embarrassing that 2025 ended as it did. It was always a company that NN should have fully taken over.38 min sitten · Muokattu38 min sitten · MuokattuIt's a falling knife. Hands off. Falling since 2024.·35 min sittenCouldn't agree more. They haven't been skilled and aggressive enough - and still aren't. It's long since Crunch Time and from now until summer they really need to shift into a completely different gear if they are to break out of this deadlock they've gotten into. I don't think this tactic of playing on being a "solid" company that earns "good money" is a discourse that will do anything but harm. The market has understood that they still have a solid business running. But the market has also long since smelled that it's a business that almost lacks both 4th and 5th gear in the gearbox. One must at least hope that Mike "I've never missed a budget" D has done exactly what it takes to keep it going: they've aimed so low now that they can't avoid missing (and maybe they've set it up so they can upgrade later in the year, who knows). But I just think it would be a very good time to step on the gas in some way. It fundamentally surprises me that they aren't trying to find a way to direct focus elsewhere through some aggressive acquisitions. It just seems so incredibly one-sided by now, all this NN vs LLY talk. There's a lot of talk about which of them wins the obesity race - but in the long run, it's also about who manages to do something other than put everything into chasing obesity market shares and the market's favor based on who just has a couple of percent better this than the others... It's become too crazy, you know..
- ·1 t sittenThe whales have now recovered after the rocket-fireworks and are ready to inject money into Novo again. BIG money. I.e. whale money. We can therefore expect the price to rise to 240 tomorrow, then a bit more subdued up towards 280 by the end of the month. Then FOMO will arise. The scaredy-cats will join the train again, and then, well, the rest is history·10 min sittenIt continues to trickle towards 220 tomorrow.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 056 | - | - | ||
| 455 | - | - | ||
| 155 | - | - | ||
| 1 055 | - | - | ||
| 45 | - | - |
Ylin
240,3VWAP
Alin
230,85VaihtoMäärä
3 037,4 13 000 452
VWAP
Ylin
240,3Alin
230,85VaihtoMäärä
3 037,4 13 000 452
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| ABG Sundal Collier ASA | 153 | 153 | 0 | 153 |
| Anonyymi | 13 000 299 | 13 000 299 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| ABG Sundal Collier ASA | 153 | 153 | 0 | 153 |
| Anonyymi | 13 000 299 | 13 000 299 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
2025 Q4 -tulosraportti
27 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
7,95 DKK/osake
Irtoamispäivä 27.3.
4,91%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 min sittenIsn't it a bit wild that nicorette is allowed to cost so much? I don't understand why they are allowed to sell so expensively and us naive Novo supporters are punished with the regulation whip by the dominatrix.
- ·2 min sittenMedical researchers have discovered that semaglutide can reverse the debilitating tissue damage caused by osteoarthritis, the world's most common form of arthritis. The drug behind Ozempic and Wegovy is best known for treating type 2 diabetes and helping people lose weight. But the new study showed that semaglutide appears to protect joints in mice through a mechanism that is not about relieving pressure through weight loss. Instead, the drug reprograms the metabolism of cells that synthesize and maintain healthy cartilage, allowing them to generate more energy. "This work not only highlights the potential off-target effect of semaglutide as an effective drug for treating metabolic osteoarthritis," the team from China and the USA writes in their published paper, "but also reveals a weight-loss-independent repair mechanism." In addition to mouse experiments, the researchers also conducted a randomized human trial to assess the effects of semaglutide on pain, mobility, and tissue degradation in individuals with osteoarthritis and obesity. Link is found on pro investér Where the full link can be read
- ·35 min sittenTo all the pessimists!!! USA is recovering and Novo at 237 😂 Sleep well 💤2 min sitten2 min sittenDamn it, I hope it can wait a bit until I get my deposit back so that I can lose that money too
- ·1 t sittenJust bring on the deals that can signal an aggressive approach. One could suitably start by entering the fray regarding Nanexa… what negotiations are ongoing is impossible to figure out, but it's embarrassing that 2025 ended as it did. It was always a company that NN should have fully taken over.38 min sitten · Muokattu38 min sitten · MuokattuIt's a falling knife. Hands off. Falling since 2024.·35 min sittenCouldn't agree more. They haven't been skilled and aggressive enough - and still aren't. It's long since Crunch Time and from now until summer they really need to shift into a completely different gear if they are to break out of this deadlock they've gotten into. I don't think this tactic of playing on being a "solid" company that earns "good money" is a discourse that will do anything but harm. The market has understood that they still have a solid business running. But the market has also long since smelled that it's a business that almost lacks both 4th and 5th gear in the gearbox. One must at least hope that Mike "I've never missed a budget" D has done exactly what it takes to keep it going: they've aimed so low now that they can't avoid missing (and maybe they've set it up so they can upgrade later in the year, who knows). But I just think it would be a very good time to step on the gas in some way. It fundamentally surprises me that they aren't trying to find a way to direct focus elsewhere through some aggressive acquisitions. It just seems so incredibly one-sided by now, all this NN vs LLY talk. There's a lot of talk about which of them wins the obesity race - but in the long run, it's also about who manages to do something other than put everything into chasing obesity market shares and the market's favor based on who just has a couple of percent better this than the others... It's become too crazy, you know..
- ·1 t sittenThe whales have now recovered after the rocket-fireworks and are ready to inject money into Novo again. BIG money. I.e. whale money. We can therefore expect the price to rise to 240 tomorrow, then a bit more subdued up towards 280 by the end of the month. Then FOMO will arise. The scaredy-cats will join the train again, and then, well, the rest is history·10 min sittenIt continues to trickle towards 220 tomorrow.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 056 | - | - | ||
| 455 | - | - | ||
| 155 | - | - | ||
| 1 055 | - | - | ||
| 45 | - | - |
Ylin
240,3VWAP
Alin
230,85VaihtoMäärä
3 037,4 13 000 452
VWAP
Ylin
240,3Alin
230,85VaihtoMäärä
3 037,4 13 000 452
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| ABG Sundal Collier ASA | 153 | 153 | 0 | 153 |
| Anonyymi | 13 000 299 | 13 000 299 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| ABG Sundal Collier ASA | 153 | 153 | 0 | 153 |
| Anonyymi | 13 000 299 | 13 000 299 | 0 | 0 |